Skip to main content
    PeptideAuthority
    Fact-checked by the Peptide Authority Editorial Board · Last reviewed:
    Share:X PostLinkedIn
    Healing & Recovery•Updated 2026-02-01•5 min read

    What Is Thymosin Beta-4? Benefits, Research & Safety

    A 43-amino acid peptide naturally present in all cells, fundamental to tissue repair, cell migration, and regeneration processes throughout the body.

    Share:X PostLinkedIn
    Also known as:
    Tβ4
    TB4
    TMSB4X
    DAnimal/cell evidence onlyUK: Unlicensed (UK)WADA: Prohibited in sport

    UK summary: Not a licensed UK medicine. The full-length parent protein of TB-500; investigated in some early human cardiac and wound-healing trials. Treated by WADA as prohibited under the growth-factors category.

    Quick Facts

    Category
    Healing & Recovery
    Half-Life
    Relatively short plasma half-life; effects may persist longer due to intracellular mechanisms
    UK Status
    Not licensed for human therapeutic use. Research compound.
    EU Status
    Orphan drug designation for some indications. Not generally approved.

    Overview

    Thymosin Beta-4 (Tβ4) is a 43-amino acid, water-soluble peptide that is expressed in virtually all cell types throughout the human body. It is one of the most abundant intracellular proteins, with particularly high concentrations in blood platelets, wound fluid, and developing tissues. Originally isolated from the thymus gland, hence its name, Thymosin Beta-4 has since been found to play fundamental roles far beyond immune function. Its primary biological role is as an actin-sequestering protein, binding to monomeric actin (G-actin) and regulating the dynamics of the cellular cytoskeleton—essential for cell movement and division. The discovery of Thymosin Beta-4's profound effects on wound healing and tissue regeneration has generated significant scientific and clinical interest. The peptide promotes cell migration, angiogenesis, and the differentiation of stem cells, making it a focus of regenerative medicine research. Clinical trials have investigated Thymosin Beta-4 for wound healing, cardiac repair following myocardial infarction, and treatment of dry eye syndrome. While results have been promising, regulatory approval for most applications remains pending. TB-500 is a synthetic peptide based on the active region of Thymosin Beta-4 and is often used in research settings as a more accessible alternative to the full molecule.
    Evidence standards summary

    Thymosin Beta-4 — evidence and risk at a glance

    Twenty standard modules scored against the Peptide Authority evidence grading methodology. Missing modules indicate the field has not yet been characterised editorially — treat absences as uncertainty rather than reassurance.

    01Evidence snapshot

    DAnimal/cell evidence onlyOverall grade against our evidence grading methodology.

    Not a licensed UK medicine. The full-length parent protein of TB-500; investigated in some early human cardiac and wound-healing trials. Treated by WADA as prohibited under the growth-factors category.

    02Human evidence grade

    ETheoretical / insufficientStrength of evidence from published human trials.

    03Preclinical evidence grade

    BModerate human evidenceAnimal-model and in-vitro evidence quality.

    04Regulatory status

    • UK: Not licensed for human therapeutic use. Research compound.
    • EU: Orphan drug designation for some indications. Not generally approved.
    • Notes: Thymosin Beta-4 has received orphan drug designation for certain conditions but remains largely in clinical development. RegeneRx has advanced several Tβ4-based products through clinical trials.

    05Approved medical uses

    None in the UK or EU as a finished medicine. (Or: not yet documented; treat as absence rather than approval.)

    06Unapproved / promotional claims

    • Faster healing of any injury.
    • Heart-attack recovery accelerator.
    • Safe for daily long-term injection.

    07Common internet claims

    • Marketed alongside TB-500 as the 'full' thymosin beta-4 product.
    • Sold by online retailers as research-only injectable.
    • Promoted by athletes despite WADA prohibition.

    08Claim vs evidence

    ClaimEvidenceHuman evidence?Regulatory concernSafer wording
    “Repairs cardiac tissue after heart attack”CLimitedHighEarly-phase human cardiac trials investigated Tβ4 for myocardial repair; outcomes data did not produce a licensed product.
    “Heals injuries faster than TB-500”ENoHighNo head-to-head human trials of full Tβ4 vs the commercial TB-500 fragment exist.
    “Safe for long-term use”ENoHighLong-term human safety is not established.
    “Available from research suppliers — same molecule as clinic-grade”ENoHighGrey-market protein supply lacks identity / purity verification.

    09Safety uncertainty score

    High

    Limited human safety data; meaningful uncertainty about rare or long-term effects.

    10Known adverse signals

    • Limited human safety data outside small Phase 2 cardiac trials.
    • WADA S2 prohibited.
    • Injection-site reactions.

    11Drug-interaction uncertainty

    High

    Interaction picture sparse; meaningful uncertainty when combined with other medicines.

    12Anti-doping status

    WADA: Prohibited in sportWADA strict-liability framing applies.

    13UK legal position

    UK: Unlicensed (UK)

    Not licensed for human therapeutic use. Research compound.

    Read the full UK legal guide → BPC-157 legal status (UK)

    14EU legal position

    Orphan drug designation for some indications. Not generally approved.

    15What this page cannot tell you

    • Whether a UK-purchased vial contains TB4 at the labelled concentration.
    • Long-term oncologic risk from sustained TB4 elevation.

    16Last reviewed

    Last reviewed:

    Next review due:

    Spotted an error or something out of date? Send a correction.

    17Citation quality score

    CLimited human evidenceQuality of the sources we cite, graded against the evidence grading methodology.

    18Research gaps

    • Phase 3 trials for any indication absent.
    • Long-term healthy-adult safety unstudied.

    19Safer alternatives / established care pathways

    • NHS physiotherapy + sports-medicine pathway for tissue injury.
    • NHS cardiology pathway for cardiac concerns.

    Related Safety Centre page → Athlete anti-doping risks

    20Doctor discussion prompts

    Questions to ask a qualified clinician

    These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.

    • Is Thymosin Beta-4 a licensed UK medicine?
    • What human evidence exists beyond the early-phase cardiac trials?
    • If I'm an athlete, what is the WADA position on Tβ4 and TB-500?
    • What licensed treatments exist for my underlying injury or cardiac concern?

    Discovery & History

    Thymosin Beta-4 was first isolated from the thymus gland in 1966 by Allan Goldstein at the Albert Einstein College of Medicine. The thymus, known for its role in T-cell maturation and immune function, was the source of numerous "thymosin" peptides believed to have immunological activity. Initial research in the 1970s and 1980s focused on potential immunological applications. However, the discovery that Thymosin Beta-4 was present in virtually all cell types—not just immune tissues—suggested broader biological functions. The breakthrough came with the identification of Thymosin Beta-4 as a major actin-sequestering protein in the early 1990s. This finding revealed its fundamental role in regulating cell structure and movement. Researchers found that Tβ4 binds to G-actin with high affinity, preventing premature polymerisation and allowing controlled cytoskeletal dynamics. Subsequent research in the late 1990s and 2000s demonstrated Thymosin Beta-4's remarkable wound healing properties. Studies showed accelerated wound closure, enhanced angiogenesis, and reduced inflammation in various injury models. The peptide entered clinical trials for several indications including wound healing, cardiac repair, and dry eye disease. RegeneRx Biopharmaceuticals developed Tβ4-based therapies including RGN-259 for ophthalmic use.

    Mechanism of Action

    Thymosin Beta-4 exerts its biological effects through multiple interconnected mechanisms: **Actin Binding and Cell Motility** Tβ4 is the primary actin-sequestering protein in cells, binding to G-actin and regulating the pool of actin available for polymerisation into filaments. By controlling actin dynamics, Tβ4 enables cells to migrate efficiently—a critical process in wound healing and tissue repair. **Cell Migration Promotion** Through its effects on the cytoskeleton, Tβ4 enhances the migration of various cell types including endothelial cells, keratinocytes, and stem cells to sites of injury. This recruitment of reparative cells is essential for tissue regeneration. **Angiogenesis Stimulation** Thymosin Beta-4 promotes the formation of new blood vessels by stimulating endothelial cell migration, survival, and tube formation. Improved vascularisation enhances nutrient delivery and supports tissue repair. **Anti-Inflammatory Effects** Tβ4 modulates inflammatory responses, reducing the production of pro-inflammatory cytokines and promoting resolution of inflammation. This creates an environment more conducive to healing rather than scarring. **Stem Cell Activation** Research demonstrates that Tβ4 can activate resident stem cells and progenitor cells, promoting their differentiation toward tissue-specific cell types. This is particularly relevant in cardiac regeneration research. **Anti-Apoptotic Activity** Thymosin Beta-4 has been shown to promote cell survival by inhibiting apoptotic pathways, protecting cells from death following injury or ischemia.

    Researched Benefits

    Based on preclinical and clinical research findings:

    • 1
      Accelerated wound healing with improved tissue quality
    • 2
      Enhanced cardiac repair and regeneration following injury
    • 3
      Improved angiogenesis and blood vessel formation
    • 4
      Reduced inflammation and scarring
    • 5
      Potential benefits for dry eye syndrome
    • 6
      Possible neuroprotective effects in brain injury
    • 7
      Support for hair follicle regeneration
    • 8
      Enhanced stem cell activation and tissue regeneration

    Claim vs Evidence

    How popular claims about Thymosin Beta-4 stack up against the current research, graded using our public evidence grading methodology.

    ClaimEvidenceHuman evidence?Regulatory concernSafer wording
    “Repairs cardiac tissue after heart attack”CLimitedHighEarly-phase human cardiac trials investigated Tβ4 for myocardial repair; outcomes data did not produce a licensed product.
    “Heals injuries faster than TB-500”ENoHighNo head-to-head human trials of full Tβ4 vs the commercial TB-500 fragment exist.
    “Safe for long-term use”ENoHighLong-term human safety is not established.
    “Available from research suppliers — same molecule as clinic-grade”ENoHighGrey-market protein supply lacks identity / purity verification.

    Theoretical Dosing & Protocols

    ⚠️ Educational Only: The following information is derived from research literature and is not a prescription or recommendation. No standardised human dosing exists. Always consult a qualified healthcare professional.
    Theoretical DosageVariable depending on application and formulation; clinical trials have used various dosing regimens
    FrequencyDepends on indication and delivery method
    DurationVariable by application
    NotesThymosin Beta-4 has been studied in clinical trials for specific indications. Protocols vary significantly. Any use should be under medical supervision and preferably within clinical research frameworks.

    Administration Routes

    Routes studied in research settings (educational only):

    • Subcutaneous injection
    • Intramuscular injection
    • Topical application (eye drops for dry eye)
    • Intravenous administration (certain clinical settings)
    Half-LifeStability
    Relatively short plasma half-life; effects may persist longer due to intracellular mechanismsStable when properly stored; lyophilised forms preferred for long-term storage

    Safety Profile & Known Risks

    Commonly Reported Side Effects

    • Injection site reactions
    • Temporary fatigue or flu-like symptoms
    • Mild headache in some cases

    Rare Risks & Concerns

    • Unknown long-term effects from exogenous administration
    • Theoretical concerns regarding tumour promotion
    • Possible cardiovascular effects

    Contraindications

    • Active malignancy
    • Pregnancy and breastfeeding
    • Certain cardiovascular conditions
    • Children (limited safety data)

    UK & EU Regulatory Context

    🇬🇧 United Kingdom

    Not licensed for human therapeutic use. Research compound.

    🇪🇺 European Union

    Orphan drug designation for some indications. Not generally approved.

    Thymosin Beta-4 has received orphan drug designation for certain conditions but remains largely in clinical development. RegeneRx has advanced several Tβ4-based products through clinical trials.

    Clinical Studies Summary

    Thymosin β4 Activates Integrin-Linked Kinase and Promotes Cardiac Cell Migration and Survival

    Demonstrated Tβ4's cardioprotective mechanisms and potential for cardiac regeneration.

    Nature. 2004View on PubMed

    Thymosin beta 4: An emerging therapeutic candidate for kidney diseases.

    Finally, translational opportunities are appraised with attention to pharmacokinetics, peptide stability and delivery strategies. Key challenges moving forward include validating efficacy in additional clinically relevant models, overcoming peptide instability and completing comprehensive safety assessments.

    Peptides. 2026View on PubMed

    Thymosin beta-4 denotes new directions towards developing prosperous anti-aging regenerative therapies.

    We discovered TB4 is capable of epicardial progenitor activation, and revealed the effect is independent of hypoxic injury. By observing the above results, we believe, further discoveries and consequential postnatal administration of developmentally relevant candidate molecules such as TB4 may likely result in reversing aging processes and accelerate organ regeneration in the human body.

    Int Immunopharmacol. 2023View on PubMed

    Tβ4-Ac-SDKP pathway: Any relevance for the cardiovascular system?

    En dépit de la localisation et de la caractérisation des sites de liaison de l’Ac-SDKP dans le myocarde, d’autres études seraient nécessaires pour caractériser entièrement et cloner les récepteurs de l’Ac-SDKP.

    Can J Physiol Pharmacol. 2019View on PubMed

    Sources of variability in quantifying circulating thymosin beta-4: literature review and recommendations.

    We further highlight three factors that may confound TB4 clinical measurements and should be considered in future study design: 1) residual platelets remaining in suspension after centrifugation, 2) TB4 release following ex vivo platelet activation, and 3) specificity of assays towards posttranslational modifications.

    Expert Opin Biol Ther. 2018View on PubMed

    Thymosin beta 4 regulation of actin in sepsis.

    Given that Thymosin Beta 4 inhibits the polymerization of F-actin, it is possible that Thymosin Beta 4 decreases mortality in sepsis via the regulation of actin as well as its other anti-inflammatory properties and should be further pursued as a clinical trial in humans with sepsis.

    Expert Opin Biol Ther. 2018View on PubMed

    Registered Trials & Regulatory Status

    Registered trials
    15
    Currently recruiting
    1
    Furthest phase
    Phase 2
    Approved product
    No

    5 of 9 completed trials have never posted results. Unreported trials are not neutral: results that go unpublished are more often negative ones.

    Recombinant Human Thymosin Beta 4 for Injection(NL005) for Acute Myocardial Infarction

    PHASE2

    Status: Not Yet Recruiting · 189 participants · Beijing Northland Biotech. Co., Ltd.

    Conditions: Acute Myocardial Infarction (AMI), Acute Myocardial Infarction of Anterior Wall, Acute Myocardial Infarction With ST Elevation

    No results postedNCT07586865

    TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVD

    PHASE1/PHASE2

    Status: Recruiting · 80 participants · Hudson Biotech

    Conditions: Atherosclerotic Cardiovascular Diseases, Endothelial Dysfunction

    No results postedNCT07487363

    Efficacy and Safety Study of Thymosin Beta 4 in Patients With Acute Myocardial Infarction

    PHASE2

    Status: Completed · 90 participants · Beijing Northland Biotech. Co., Ltd.

    Conditions: Acute Myocardial Infarction

    No results postedNCT05984134

    Safety and Efficacy Study of Thymosin Beta 4 in Patients With Acute Myocardial Infarction.Infarction

    PHASE2

    Status: Completed · 62 participants · Beijing Northland Biotech. Co., Ltd.

    Conditions: Acute Myocardial Infarction

    No results postedNCT05485818

    A Study of the Safety and Efficacy of Injectable Thymosin Beta 4 for Treating Acute Myocardial Infarction

    PHASE2

    Status: Withdrawn · RegeneRx Biopharmaceuticals, Inc.

    Conditions: Acute Myocardial Infarction, ST Elevation Myocardial Infarction, STEMI

    No results postedNCT01311518

    A Phase 1b Study of Thymosin Beta 4 in Healthy Volunteers

    PHASE1

    Status: Completed · 30 participants · Beijing Northland Biotech. Co., Ltd.

    Conditions: Healthy

    No results postedNCT04555850

    A Phase 1a Study of Thymosin Beta 4 in Healthy Volunteers

    PHASE1

    Status: Completed · 54 participants · Beijing Northland Biotech. Co., Ltd.

    Conditions: Healthy

    No results postedNCT04555824

    Slow-release Tb4 Collagen and Chitosan Porous Sponge Scaffolds Skin Substitute Treatment is Difficult to Heal Wounds

    PHASE1

    Status: Completed · 20 participants · Chinese PLA General Hospital

    Conditions: Wounds

    No results postedNCT02668055

    Safety and Efficacy of Thymosin Beta 4 Ophthalmic Solution in Patients With Dry Eye

    PHASE2

    Status: Completed · 72 participants · ReGenTree, LLC

    Conditions: Dry Eye Syndrome, Dry Eye

    Results postedNCT01387347

    Comparative Study of Thymosin Beta 4 Eye Drops vs. Vehicle in the Treatment of Severe Dry Eye

    PHASE2

    Status: Completed · 9 participants · Michigan Cornea Consultants, PC

    Conditions: Dry Eye, Sjogren's Syndrome, Graft vs. Host Disease

    Results postedNCT01393132

    A Phase 1 Safety Study of the Intravenous Administration of Thymosin Beta in Healthy Volunteers

    PHASE1

    Status: Withdrawn · RegeneRx Biopharmaceuticals, Inc.

    Conditions: Myocardial Infarction, Myocardial Ischemia

    No results postedNCT00743769

    A Phase 2 Study of the Safety and Efficacy of Thymosin Beta 4 for Treating Corneal Wounds

    PHASE2

    Status: Terminated · 12 participants · ReGenTree, LLC

    Conditions: Diabetes

    Results postedNCT00598871

    Adverse event reports (FDA FAERS)

    Not applicable: no licensed product contains this peptide, so it is not reported through FAERS. This is an absence of surveillance, not evidence of safety.

    Source: ClinicalTrials.gov and openFDA. Updated automatically.

    Looking for Thymosin Beta-4?

    Source research-grade Thymosin Beta-4 from a trusted UK supplier — third-party tested with certificate of analysis.

    View at Supplier

    Frequently Asked Questions

    Questions to ask a qualified clinician about Thymosin Beta-4

    These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.

    • Is Thymosin Beta-4 a licensed UK medicine?
    • What human evidence exists beyond the early-phase cardiac trials?
    • If I'm an athlete, what is the WADA position on Tβ4 and TB-500?
    • What licensed treatments exist for my underlying injury or cardiac concern?

    UK regulatory & safety context

    BPC-157 legal status (UK)

    UK legal reference

    Athlete anti-doping risks

    Safety Centre guide

    Peptide Comparisons

    BPC-157 vs TB-500

    Compare peptides

    Related Peptides

    BPC-157

    A pentadecapeptide derived from human gastric juice, extensively researched for its potential tissue repair and regenerative properties across multiple organ systems.

    Learn more

    TB-500

    A synthetic version of the naturally occurring peptide Thymosin Beta-4, extensively researched for its roles in tissue repair, cell migration, and angiogenesis.

    Learn more

    GHK-Cu

    A naturally occurring copper-binding tripeptide researched for its roles in wound healing, skin regeneration, anti-ageing, and tissue remodelling.

    Learn more

    Explore More Peptides

    Browse our comprehensive database of research-backed peptide profiles.